Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B

Abstract

Objective:

To review efficacy and safety data of valoctocogene roxaparvovec (Roctavian) and etranacogene dezaparavovec (Hemgenix), novel gene therapies for the treatment of the life-threatening bleeding disorders hemophilia A and B, respectively.

Data Sources:

A PubMed/Google Scholar search from inception through August 11, 2023 was conducted using the following keywords: gene therapy, hemophilia A, hemophilia B, etranacogene dezaparavovec, valoctocogene roxaparvovec, and bleeding.

Study Selection and Data Extraction:

Data, including phase 1 to 3 clinical trials (non-comparator), were obtained from primary literature and package inserts. These reports evaluated clinical pharmacology, efficacy, safety, adverse events, warnings, and precautions.

Data Synthesis:

Valoctocogene phase 3 study in males (n = 134): 87% had factor VIII (FVIII) levels that at least met criteria for mild hemophilia. Etranacogene phase 3 study in males (n = 54): within 3 weeks of infusion, mean factor IX (FIX) levels had reached 26.8 IU/dL. Both therapies provided clinically and statistically significant decreases in bleeding events and prophylactic factor infusions. Most common adverse event was elevations in liver function tests that were treated with glucocorticoids.

Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:

The endogenous production of clotting factors mimics physiological production while decreasing morbidity and mortality related to bleeding events similar to the effects of existing replacement strategies. Gene therapy was also shown to increase patient quality of life.

Conclusion:

Valoctocogene and etranacogene provide another treatment for selected patients with hemophilia. Treatment for the patient with hemophilia (gene therapy vs replacement strategy) must be personalized as new clinical data are published being cognizant of drug affordability.

Keywords

bleeding etranacogene dezaparavovec gene therapy hemophilia valoctocogene roxaparvovec

Get full access to this article

View all access options for this article.

References

Srivastava

Santagostino

Dougall

, et al WFH Guidelines for the Management of Hemophilia panelists and co-authors (WFH Guidelines for the Management of Hemophilia, 3rd Edition). Haemophilia. 2020;1(suppl.):61-58. doi:10.1111/hae.14046

Mancuso

Mahlangu

Pipe

SW.

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397:630-640. doi:10.1016/S0140-6736(20)32722-7

US Food and Drug Administration. FDA approves first gene therapy for adults with severe hemophilia A. Published June 29, 2023. Accessed July 15, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia

US Food and Drug Administration. FDA approves first gene therapy for adults with severe hemophilia B. Published November 22, 2022. Accessed July 15, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b

The high price of hemophilia. Published February 1, 2020. Accessed July 20, 2023. https://www.ashclinicalnews.org/spotlight/feature-articles/high-price-hemophilia/

Meeks

Batsuli

Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016;1:657-662. doi:10.1182/asheducation-2016.1.657

Nathwani

AC.

Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2022;1:569-578. doi:10.1182/hematology.2022000388

Rangarajan

Walsh

Lester

, et al AAV5-Factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377:2519-2530. doi:10.1056/NEJMoa1708483

Pasi

Rangarajan

Mitchell

, et al Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020;382:29-40. doi:10.1056/NEJMoa1908490

10.

Pasi

Laffan

Rangarajan

, et al Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2022;27:947-956. doi:10.1111/hae.14391

11.

Ozelo

Mahlangu

Pasi

, et al GENEr8-1 Trial Group. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386:1013-1025. doi:10.1056/NEJMoa2113708

12.

Mahlangu

Kaczmarek

von Drygalski

, et al GENEr8-1 Trial Group. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388:694-705. doi:10.1056/NEJMoa2211075

13.

Miesbach

Meijer

Coppens

, et al Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131:1022-1031. doi:10.1182/blood-2017-09-804419

14.

Von Drygalski

Giermasz

Castaman

, et al Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3:3241-3247. doi:10.1182/bloodadvances

15.

von Drygalski

Gomez

Giermasz

, et al Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Adv. 2022;9:2022008886. doi:10.1182/bloodadvances.2022008886

16.

Pipe

Leebeek

FWG

Recht

, et al Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388:706-718. doi:10.1056/NEJMoa2211644

17.

Valoctocogene roxaparvovec-rvox (Roctavian™) package insert. Novato, CA: Biomarin Pharmaceutical Inc.

18.

Etranacogene dezaparvovec-drb (Hemgenix™) package insert. King of Prussia, PA: CSL Behring LLC.

19.

Samelson-Jones

George

LA.

Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74:231-247. doi:10.1146/annurev-med-043021-033013

20.

Simioni

Tormene

Tognin

, et al X-linked thrombophilia with a mutant factor IX (Factor IX Padua). N Engl J Med. 2009;361:1671-1675. doi:10.1056/Nejmoa0904377

21.

Peyvandi

Oldenburg

Friedman

KD.

A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14:248-261. doi:10.1111/jth.13215

22.

Robinson

George

Samelson-Jones

, et al Activity of a FIX- Padua transgene product in commonly used FIX: C one- stage and chromogenic assay systems following PF- 06838435 (SPK- 9001) gene delivery. Blood. 2018;132(suppl. 1):2198.

23.

Thornburg

CD.

Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Rare Dis. 2021;2:26330040211058896. doi:10.1177/26330040211058896

24.

Recht

Leebeek

Miesbach

, et al Management of infusion reactions: lessons from the phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec in adults with hemophilia B [abstract]. Res Pract Thromb Haemost. 2021;5(suppl. 2). Accessed July 22, 2023. https://abstracts.isth.org/abstract/management-of-infusion-reactions-lessons-from-the-phase-3-hope-b-gene-therapy-trial-of-etranacogene-dezaparvovec-in-adults-with-hemophilia-b/

25.

George

Monahan

Eyster

, et al Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med. 2021;385:1961-1973. doi:10.1056/NEJMoa2104205

26.

Nowrouzi

Penaud-Budloo

Kaeppel

, et al Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther. 2012;6:1177-1186. doi:10.1038/mt.2012.47

27.

Fahs

Hille

Shi

Weiler

Montgomery

RR.

A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood. 2014;123:3706-3713.

28.

Everett

Cleuren

ACA

Khoriaty

Ginsburg

Murine coagulation factor VIII is synthesized in endothelial cells. Blood. 2014;123:3697-3705.

29.

Nathwani

Reiss

Tuddenham

, et al Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014:371. doi:10.1056/NEJMoa1407309

30.

Nathwani

Reiss

Tuddenham

, et al Adeno-associated mediated gene transfer for hemophilia B:8 Year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer. Blood. 2018;132(suppl. 1):491. doi:10.1182/blood-2018-99-118334

31.

Tatsumi

Ohashi

Mukobata

, et al Hepatocyte is a sole cell type responsible for the production of coagulation factor IX in vivo. Cell Med. 2012;3:25-31. doi:10.3727/215517912X639496

32.

Mullard

Gene therapy community grapples with toxicity issues, as pipeline matures. Nat Rev Drug Discov. 2021;20:804-805. doi:10.1038/d41573-021-00164-x

33.

George

Ragni

Rasko

JEJ

, et al Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther. 2020;28:2073-2082. doi:10.1016/j.ymthe.2020.06.001

34.

Fletcher

Jenner

Pembroke

Holland

Khair

The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet J Rare Dis. 2022;17:155. doi:10.1186/s13023-022-02256-2

35.

Tice

Walton

Herce-Hagiwara

, et al Gene therapy for hemophilia B and an update on gene therapy for hemophilia A. Effectiveness and Value; Evidence Report. Institute for Clinical and Economic Review, December 22, 2022. https://icer.org/assessment/hemophilia-a-and-b-2022/

36.

McNeish

. Hemophilia’s Crippling Cost. Johns Hopkins Bloomberg School of Public Health Global Health Now. Published December 12, 2018. Accessed August 8, 2023. https://globalhealthnow.org/2018-12/hemophilias-crippling-cot